Ukr.Biochem.J. 2018; Volume 90, Issue 6, Nov-Dec, pp. 62-69


Immunogenicity assay of KatG protein from Mycobacterium tuberculosis in mice: preliminary screening of TB vaccine

P. Purkan1, R. Budiyanto1, R. Akbar1, S. P. A. Wahyuningsih2, W. Retnowati3

1Biochemistry Division, Chemistry Department, Faculty of Sciences and Technology, Airlangga University, Campus C, Jl. Mulyorejo-Surabaya, Indonesia;
2Biology Department, Faculty of Sciences and Technology, Airlangga University, Campus C, Jl. Mulyorejo-Surabaya, Indonesia;
3Microbiology Department, Faculty of Medicine, Airlangga University, Campus C, Jl. Moestopo-Surabaya, Indonesia;

The tuberculosis (TB) disease is still widely found even though BCG vaccine given to many people. Ineffectiveness of the BCG vaccine is one of causes that make the difficulties in preventing TB transmission. Objective of the research was to determine the immunogenicity of KatG protein of M. tuberculosis clinical isolate L19 in mice. The KatG protein as antigen was prepared by expression of the katG gene of M. tuberculosis clinical isolate L19 in Escherichia coli BL21 using pColdII-DNA vector. After purification by affinity chromatography, the KatG was vaccinated to mice to detect its immunogenicity. The expression of katG in E. coli BL21 could result in KatG protein with molecular weight 80 kDa in sodium dodecyl sulfate gel electrophoresis (SDS-PAGE). The pure KatG protein could significantly stimulate the immune response of mice by triggering the antibodies production of IgG1, IgG2a, IgG2b, IgG2c, IgG3, and IgM. The highest antibody level was obtained when the mice were vaccinated by KatG L19 with the dose of 45 μg/ml. Of the antibodies, the IgG2c isotype was dominantly produced in the blood serum. The KatG protein exhibited a high immunogenici­ty in mice, so it is possible to develop as a vaccine candidate for TB. A clinical test should be performed in a future to ensure its safety as a therapeutic protein.

Keywords: , , , ,


  1. Tuberculosis in Indonesia – Health and Medical Concerns [Internet]. [cited 2015 November 25]. Available from:
  2. Bold TD, Banaei N, Wolf AJ, Ernst JD. Suboptimal activation of antigen-specific CD4+ effector cells enables persistence of M. tuberculosis in vivo. PLoS Pathog. 2011 May;7(5):e1002063. PubMed, PubMedCentral, CrossRef
  3. Maryanne EC, Jay SK. Understanding, Controlling, and Preventing Infectious Diseases. In: Sarah SL, Larry KP, Charles GP, eds. Principles and Practice of Pediatric Infectious Diseases. 4th Ed, United States: Elsevier Inc; 2012: 76-83.
  4. Kowalewicz-Kulbat M, Locht C. BCG and protection against inflammatory and auto-immune diseases. Expert Rev Vaccines. 2017 Jul;16(7):1-10.
    PubMed, CrossRef
  5. Li Z, Howard A, Kelley C, Delogu G, Collins F, Morris S. Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences. Infect Immun. 1999 Sep;67(9):4780-6. PubMed, PubMedCentral
  6. Purkan, Ihsanawati, Syah YM., Retnoningrum DS, Noer AS., Shigeoka S, Natalia D. Novel mutations in katG gene of a clinical isolate of isoniazidresistant Mycobacterium tuberculosis. Biologia. 2012; 67(1): 41-47.  CrossRef
  7. Purkan, Ihsanawati, Natalia D, Syah YM, Retnoningrum DS, Kusuma HS. Mutation of katG in a clinical isolate of Mycobacterium tuberculosis: effects on catalase-peroxidase for isoniazid activation. Ukr Biochem J. 2016 Sep-Oct;88(5):71-81. PubMed, CrossRef
  8. Purkan P, Wahyuningsih SPA, Retnowati W, Amelia D, Alimny AN. Structure – Activity Relationship of Mutant KatG from INH resistant Mycobacterium tuberculosis. J Pure Appl Microbiol. 2017; 11(2): 695-701.  CrossRef
  9. Wengenack NL, Lane BD, Hill PJ, Uhl JR, Lukat-Rodgers GS, Hall L, Roberts GD, Cockerill FR 3rd, Brennan PJ, Rodgers KR, Belisle JT, Rusnak F. Purification and characterization of Mycobacterium tuberculosis KatG, KatG(S315T), and Mycobacterium bovis KatG(R463L). Protein Expr Purif. 2004 Aug;36(2):232-43. PubMed, CrossRef
  10. McNamara M, Tzeng SC, Maier C, Zhang L, Bermudez LE. Surface proteome of “Mycobacterium avium subsp. hominissuis” during the early stages of macrophage infection. Infect Immun. 2012 May;80(5):1868-80. PubMed, PubMedCentral, CrossRef
  11. Chandler JC, Sutherland MD, Harton MR, Molins CR, Anderson RV, Heaslip DG, Bosio CM, Belisle JT. Francisella tularensis LVS surface and membrane proteins as targets of effective post-exposure immunization for tularemia. J Proteome Res. 2015 Feb 6;14(2):664-75.  PubMed, PubMedCentral, CrossRef
  12. Sambrook JF, Russell DW. Molecular Cloning: A Laboratory Manual, 3rd Ed. Vols.3, Cold Spring Harbor Laboratory Press, New York; 2001: pp. 286-301.
  13. Borghesi L, Milcarek C. From B cell to plasma cell: regulation of V(D)J recombination and antibody secretion. Immunol Res. 2006;36(1-3):27-32. PubMed, CrossRef
  14. Pier GB, Lyczak JB, Wetzler LM. Immunology, Infection, and Immunity. ASM Press, American; 2004:pp. 156-172.
  15. Frey A, Meckelein B, Externest D, Schmidt MA. A stable and highly sensitive 3,3′,5,5′-tetramethylbenzidine-based substrate reagent for enzyme-linked immunosorbent assays. J Immunol Methods. 2000 Jan 13;233(1-2):47-56. PubMed, CrossRef
  16. Coler RN, Campos-Neto A, Ovendale P, Day FH, Fling SP, Zhu L, Serbina N, Flynn JL, Reed SG, Alderson MR. Vaccination with the T cell antigen Mtb 8.4 protects against challenge with Mycobacterium tuberculosis. J Immunol. 2001 May 15;166(10):6227-35. PubMed, CrossRef
  17. Billeskov R, Tan EV, Cang M, Abalos RM, Burgos J, Pedersen BV, Christensen D, Agger EM, Andersen P. Testing the H56 Vaccine Delivered in 4 Different Adjuvants as a BCG-Booster in a Non-Human Primate Model of Tuberculosis. PLoS One. 2016 Aug 15;11(8):e0161217. PubMed, PubMedCentral, CrossRef
  18. Aagaard C, Hoang TT, Izzo A, Billeskov R, Troudt J, Arnett K, Keyser A, Elvang T, Andersen P, Dietrich J. Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose. PLoS One. 2009 Jun 16;4(6):e5930. PubMed, PubMedCentral, CrossRef
  19. Gupta K, Verma I, Khuller G, Mahajan R. KatG protein: a novel marker for differential diagnosis of Mycobacterium avium complex infection. Indian J Med Microbiol. 2010 Jul-Sep;28(3):221-6. PubMed, CrossRef
  20. Billeskov R, Lindenstrøm T, Woodworth J, Vilaplana C, Cardona PJ, Cassidy JP, Mortensen R, Agger EM, Andersen P. High Antigen Dose Is Detrimental to Post-Exposure Vaccine Protection against Tuberculosis. Front Immunol. 2018 Jan 15;8:1973.  PubMed, PubMedCentral, CrossRef
  21. Brennan MJ, Thole J. Tuberculosis vaccines: a strategic blueprint for the next decade. Tuberculosis (Edinb). 2012 Mar;92 Suppl 1:S6-13.
    PubMed, CrossRef
  22. de Paus RA, van Meijgaarden KE, Prins C, Kamphorst MH, Arend SM, Ottenhoff THM, Joosten SA. Immunological characterization of latent tuberculosis infection in a low endemic country. Tuberculosis (Edinb). 2017 Sep;106:62-72. PubMed, CrossRef
  23. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, Mahomed H, McShane H; MVA85A 020 Trial Study Team. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013 Mar 23;381(9871):1021-8. PubMed, PubMedCentral, CrossRef
  24. Tetramethylbenzidine [Internet]. [cited 2015 June 25]. Available from:,3%27,5,5%27-Tetramethylbenzidine.

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.